晚期非小细胞肺癌抗血管生成治疗:文献复习及病例报道  

Anti-angiogenesis treatment in advanced non-small cell lung cancer : case report and review of literature

作　　者：丁林[1] 江志敏[1] 李怀 李青剑 姚和瑞[1] 

机构地区：[1]中山大学孙逸仙纪念医院肿瘤科,广州510120 [2]顺德区龙江医院肿瘤科,广东佛山528318

出　　处：《岭南现代临床外科》2015年第6期656-660,共5页Lingnan Modern Clinics in Surgery

基　　金：国家自然科学基金(81372819;81572596);教育部博士点基金(20120171110075);广州市科技计划(2014J4100170);中山大学青年教师重点培育项目(13ykzd14)

摘　　要：肺癌是我国死亡率最高的癌症,其中非小细胞肺癌占多数。近年来研究表明,抗血管生成药物在多种实体瘤包括非小细胞肺癌中表现出了显著的疗效。阿帕替尼作用于血管内皮生长因子受体(VEGFR),临床研究证实目前其主要适应症为晚期胃癌。近年来在晚期非小细胞肺癌患者中应用阿帕替尼的临床实践日益增多,但相关报道极少。现将本院在晚期非小细胞肺癌中应用阿帕替尼的临床病例报告如下并做相关文献复习。Lung cancer leads in the highest mortality rate of cancers in our country, the majority of which is non-small-cell lung caner. Latest studies prove that anti-angiogenesis drugs exert a remarkable effect on the therapy of NSCLC. By acting on VEGFR, apatinib is testified to treat patients diagnosed with advanced gastric carcinoma. Numerous clinical practices have been applied for the past years in which apatinib treat the patients with NSCLC. However, relevant reports are rarely seen.Therefore we tend to report two cases in which apatinib is used in the treatment of advanced lung cancer and review the relevant articles.

关 键 词：非小细胞肺癌 抗血管生成 阿帕替尼 

分 类 号：R734.2[医药卫生—肿瘤]